Chiron Real Estate Inc. Announces $100 Million Strategic Convertible Perpetual Preferred Equity Investment Led by Maewyn Capital Partners
“This growth equity investment represents an important milestone in the repositioning of Chiron. Maewyn’s capital provides long-term flexibility and is expected to accelerate our transition toward higher-return opportunities across the healthcare real estate spectrum. We are focused on disciplined capital allocation and believe this investment further aligns our capital structure with our objective of driving long-term earnings growth,” said
“I have known
Strategic Rationale and Benefits
- Supports portfolio repositioning: Provides capital to accelerate Chiron’s transition toward higher-return investments, including senior housing and other targeted healthcare sectors.
- Attractive cost of capital: Structured to provide long-term, flexible capital while preserving balance sheet strength.
- Institutional validation: Reflects confidence in Chiron’s platform, strategy, and ability to execute a disciplined capital allocation framework.
-
Enhances corporate governance:
Charles P. Fitzgerald will be joining the Company’s board of directors (the “Board”) as an independent director following the Company’s annual meeting of stockholders to be held onMay 20, 2026 . -
Alignment: A separate Maewyn affiliate owns 53,434 shares of common stock, purchased prior to this transaction, representing approximately
$2 million of invested capital.
Terms of the
-
The Company will sell an aggregate of
$100 million of Series C convertible perpetual preferred stock (the “Series C Preferred Stock”), either in full or in multiple tranches (subject to certain closing conditions). All capital must be called within six months from today's date. - 6.00% per annum dividend yield, payable quarterly in cash, which will increase after the fourth anniversary of the final draw if the Series C Preferred Stock is still outstanding.
-
Holders have the option to convert the Series C Preferred Stock into shares of common stock of the Company at
$43.00 per share (“Conversion Price”) at any time. Three years after the final draw, the Company has the option to convert the Series C Preferred Stock to common stock if the volume-weighted average price exceeds 20.0% above the Conversion Price for 45 consecutive trading days. - The Company may redeem the Series C Preferred Stock at par at any time, after the fourth anniversary of the final draw. If the Series C Preferred Stock is redeemed, the Company will issue a warrant to the holders at the then-effective Conversion Price with a 5-year term.
- The Series C Preferred Stock does not have a make-whole provision or make-whole grid commonly found in redemption features of convertible securities.
-
Maewyn will have the right to appoint one representative to the Board.
Charles P. Fitzgerald will be the initial designee and will be appointed following the Company’s 2026 Annual Stockholders’ meeting onMay 20, 2026 .Mr. Fitzgerald brings extensive REIT sector and investment management experience across a career spanning nearly 30 years, including portfolio management positions atJP Morgan Investment Management ,High Rise Capital Management and V3 Capital Management, which he founded and served as its Managing Partner.
CBRE Investment Banking served as lead financial advisor to Maewyn in connection with the transaction, while
About Chiron
Chiron is a real estate investment trust (“REIT”) focused on investing in the future of healthcare. At Chiron we strive to deliver value at the intersection of care, capital and real estate. Additional information about Chiron can be obtained on its website at www.chironre.com.
About
Maewyn’s approach reflects a long and proven history of disciplined, value-oriented investing, combined with a collaborative philosophy that emphasizes partnership with management teams, boards, and other stakeholders. The firm builds on the heritage of Mr. Fitzgerald’s prior firm, V3 Capital Management, extending a track record of thoughtful capital allocation, active engagement, and durable value creation within the real estate sector.
Forward-Looking Statements
Certain statements contained herein may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, and it is the Company’s intent that any such statements be protected by the safe harbor created thereby. These forward-looking statements are identified by their use of terms and phrases such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "should," "plan," "predict," "project," "will," "continue" and other similar terms and phrases, including references to assumptions and forecasts of future results. Except for historical information, the statements set forth herein including, but not limited to, any statements regarding the investment in our Series C Preferred Stock or the terms of the investment agreement by
View source version on businesswire.com: https://www.businesswire.com/news/home/20260506222993/en/
Investor Relations:
Email: Investors@chironre.com
Phone: 202.524.6869
Source: